TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05681754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: RCT using hydraulic calcium silicate sealer and L-PRF + GTR
Description: Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR +/- LPRF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: RCT using conventional sealer and L-PRF + GTR
Description: Endodontic treatment with conventional sealer followed by periodontal treatment with PRF + GTR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: RCT using hydraulic calcium silicate sealer and GTR
Description: Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: RCT using conventional sealer and GTR (bone substitute + collagen membrane)
Description: Endodontic treatment with conventional sealer followed by periodontal treatment with GTR only
Study: NCT04618978

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PSG and actigraphy recording
Description: Gold standard: electromyographic recording of tibialis anterior muscle during full night polysomnography (PSG).~The new generation actigraphs devices Actiwatch will be combined to PSG as a screening tool: MotionWatch will be placed on the dorsum of feet to record).
Study: NCT05123313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprescribing intervention
Description: The intervention is comprised of a minimum of three consultations with a general practitioner (GP), where adjustment of the patient's medication is made according to the patient's preference, goals and needs~Consultation 1: Patient and GP discuss how the patient feels about their medical treatment, and the GP provides the patient with written material for the patient to prepare prior to the next consultation.~Consultation 2: A clinical pharmacist have beforehand examined the patient's medication list and provided suggestions to the GP on which drugs can be deprescribed. The patient and GP discuss the patient's preferences and initiate deprescribing initiatives aligned with the patient's priorities.~Consultation 3: Patient and GP follow up on the changes initiated and initiate new deprescribing initiatives if such can be identified. If needed, subsequent consultations (Consultation X) are planned until the patient and GP consider the patient's medical treatment optimal.
Study: NCT06271902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Singapore Youth Shoulder Overuse Injury Prevention Program
Description: A 10-minute, 4-exercises program that targets shoulder eccentric external rotation strength, shoulder internal rotation range of morion, and thoracic rotation range of motion. The topic for the 45-minute educational workshop will be on overuse injuries among youth athletes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower body stretching program
Description: A 10-minute, 5-stretches sham exercise program that does not target the upper extremity and are only held for 10 seconds.
Study: NCT05899322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Intervention for PTSD Spanish Speaking Adolescents
Description: This treatment ranges from 1-3 sessions which last 30-50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the adolescent with optional parent involvement. The first session will also teach the adolescent a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the adolescent's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that address the adolescent's symptoms. This treatment will be delivered via telehealth and all materials have been developed in both Spanish and English.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Treatment as Usual
Description: Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
Study: NCT06262139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT218 injection
Description: a targeted magnetic resonance imaging contrast agent
Study: NCT06231355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Performing paravertebral nerve block with lipo-bupivacaine
Description: Paravertebral block is performed using liposomal bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Performing paravertebral nerve block with bupivacaine
Description: Paravertebral block is performed using bupivacaine.
Study: NCT06241235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study: NCT06439901

Intervention type: OTHER
Group type: OTHER
Intervention: Screening
Description: A first step to identify and recruit people eligible for screening,

Intervention type: OTHER
Group type: OTHER
Intervention: Inclusion
Description: A second step for inclusion of participants, with an online self-questionnaire and information, and an inclusion visit to the health center,

Intervention type: OTHER
Group type: OTHER
Intervention: Chest CTscan and follow-up
Description: A third step with an initial CTscan, with dual interpretation and appropriate management of participants, including follow-up care.
Study: NCT04908371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Trunk Block
Description: It is one type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 20ml) injected at the trunks of the brachial plexus in order to produce the anesthesia of the whole upper extremity of the patients scheduled for upper limb surgery. SeTB will be performed as a two-injection technique. One at the side of the neck (interscalene groove) of the affected upper limb, injections will be made near the superior trunk (5mL) and follow by redirection of the needle under ultrasound guidance to inject the LA to middle trunk (5mL). Then the second skin puncture will be made near the upper part mid-collar bone (supraclavicular fossa) to inject the LA to the inferior trunk (10mL).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)
Description: It is another type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 30ml) injected at the interscalene groove and supraclavicular fossa, so two-injection technique will be adopted. The first skin puncture will be near the side of the neck (interscalene groove) of the affected upper limb (15mL) and then the second skin puncture will also be made near the upper mid-collar bone (supraclavicular fossa) to inject 15mL of LA.
Study: NCT05680779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound-guided percutaneous neuromodulation
Description: It´s an intervention of physiotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: dry needling
Description: It´s an intervention of physiotherapy
Study: NCT06367036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical hypericum perforatum oil intervention
Description: The research nurse working in the CICU applied 5-6 drops of hypericum perforatum oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied.
Study: NCT04776057

Intervention type: OTHER
Group type: OTHER
Intervention: catarct surgery with toric intra ocular lenses
Description: rotation stability of toric intraocular lenses between sitting or routine settings (sitting, going around) after cataract operation

Intervention type: OTHER
Group type: OTHER
Intervention: catarct surgery with toric intra ocular lenses
Description: rotation stability of toric intraocular lenses between sitting or routine settings (sitting, going around) after cataract operation
Study: NCT05189236

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control Group (Only Algorithm of Febrile Neutropenia Management)
Description: Common Procedure Steps~1. The child is admitted to the unit and evaluated.~2. The objective of the study is explained to the children and children's parents, and their consent is obtained after they have read and signed the informed consent form.~3. The inclusion and exclusion criteria are evaluated.~4. The group of the child to be included in the study is determined in accordance with the randomization order.~5. The first section of the patient information and follow-up form is filled out.~6. The algorithm of Febrile Neutropenia Management is applied. The room temperature is kept constant at 21-24 degrees.~Procedure Steps for Control Group:~1. Common procedure steps are followed.~2. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)
Description: Procedure Steps for Experiment Group:~1. Common procedure steps are followed.~2. Cold steam is continuously applied until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).~3. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form from the time the patient is admitted until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).
Study: NCT05500092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Patients randomized to the Nivolumab + Platinum Doublet Chemotherapy only arm will receive three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) with sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients randomized to the Nivolumab + Platinum Doublet Chemotherapy only arm will receive three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) with sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (8gy x 3)
Description: sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum Doublet
Description: Standard of care doublet platinum therapy
Study: NCT05509842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be used to apply rTMS to targeted locations marked on the structural MRI using a frameless infrared stereotactic neuronavigation system (Brainsight, Rogue Research).
Study: NCT05874986

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance training
Description: 12-week resistance training intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance training
Description: 12-week resistance training intervention
Study: NCT05317910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUSIC CARE
Description: Relaxation-type receptive musical intervention technique. The standardized 20-minute musical sequence is broken down into several phases that gradually lead the patient to relaxation using the new U-Mount technique \[1, 2\] (Figure 1). The effect works by reducing the musical rhythm, orchestral formation, frequencies and volume (the U descending phase). After a maximum relaxation phase (lower part of the U), a re-activating phase (ascending branch of the U) is followed.
Study: NCT05209386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dimension-Based Statistical Learning
Description: Each participant will complete self-paced blocks of stimuli that will first establish a baseline for neural activity and behavioral responses with clear speech, and will then record responses for experimentally manipulated blocks to introduce 1) speech-in-noise and 2) a Canonical-Reverse block to model an accent. Auditory stimuli will be adjusted to a comfortable level for each participant as determined by a calibration process completed by the participant. Each block involves listening to sound via earphones and making a categorical decision between initial consonants (/b/ or /p/) by tapping a button to indicate the word heard by the participant.
Study: NCT04360681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: BID dosing, and a max daily dose of 1.6 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT05500092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum Doublet
Description: Standard of care doublet platinum therapy
Study: NCT05201976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtually administered Cardiac Rehab program
Description: Virtual cardiac rehab program delivered through the CardaHealth platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care in person Cardiac Rehab Program
Description: Clinically ordered standard of care cardiac rehab program (in-person).
Study: NCT06111079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin discontinuation
Description: Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin continuation
Description: Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
Study: NCT05800639

Intervention type: PROCEDURE
Intervention: Ophthalmic surgery
Description: Ophthalmic surgery will be performed as standard practice of our institution.

Intervention type: PROCEDURE
Intervention: Ophthalmic surgery
Description: Ophthalmic surgery will be performed as standard practice of our institution.

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: General anesthesia will be performed as standard practice of our institution.

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: General anesthesia will be performed as standard practice of our institution.
Study: NCT05657730

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water Kefir beverage
Description: Participants will consume the water kefir beverage for two weeks.
Study: NCT05841147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Intravenous administration of tirofiban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Intravenous administration of normal saline
Study: NCT04745208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation based education
Description: high fidelity simulation with moulage
Study: NCT05009368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Treatment A
Description: CTL0901, single dose, daily, repeated oral administration for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Treatment B
Description: CTL0902, single dose, daily, repeated oral administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Treatment C
Description: CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Treatment C
Description: CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days
Study: NCT06208826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripamab, IV, 240mg, every 3 weeks for 15 cycles

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Radiation Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy agent
Study: NCT05888324

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires by phone at 1 and 6 months after inclusion
Study: NCT06198530

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training in NLCs
Description: In the nurse-led clinics(NLCs) training group, CCT was given twice a week during 1-6 months and once a week during 7-12 month in nursing clinic. There is 60 minutes at a time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training in home
Description: In the home-based training group, CCT was given four times a week during 1-6 months and twice a week during 7-12 month in nursing clinic. There is 30 minutes at a time. Nurses teach patients to acquire and carry out CCT at home during hospitalization. Nurses set the daily reminder function at 9:00am through training system.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cognitive training in tradition
Description: In the traditional training group, the Home Cognitive Training Manual for Alzheimer's Disease compiled by our research team was distributed.
Study: NCT05663060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula
Description: Probiotic Formula
Study: NCT04800692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin 10 mg/kg
Description: 10mg/kg of Tetrahydrobiopterin daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin 20 mg/kg
Description: 20mg/kg of Tetrahydrobiopterin daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Ascorbate
Description: 3300 mg of l-ascorbate once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Ascorbate
Description: 3300 mg of l-ascorbate once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: 3400mg of l-arginine once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: 3400mg of l-arginine once daily
Study: NCT04908293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biorepair toothpaste
Description: Use of New Biorepair Advanced Sensitive for home oral care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate toothpaste
Description: Use of Colgate toothpaste for home oral care.
Study: NCT06461546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: * Imlifidase (POD0, pre-transplantation), imlifidase, 0.25 mg/kg over a period of 15 minutes, prior to transplantation.~* Dose Adjustment Criteria~FC-XM screening and single antigen will be performed after 6 hours of imlifidase infusion, It will take 3 hours to obtain the results, respectively:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - 2nd Imlifidase infusion will be required (imlifidase dose: 0.25mg/Kg).~FC-XM screening and single antigen will be performed after 2 hours of the 2nd Imlifidase infusion:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - The scheduled kidney transplant will be canceled.
Study: NCT05869539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Tumor-infiltrating lymphocyte transfer with ANV419
Description: The study uses a personalized IMP (investigational medicinal product), i.e. TIL product in combination with ANV419.~Day 0: Autologous TIL: (minimum 5 x 10\^9 and up to 2x 10\^11 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion. Actual body weight will be used to calculate the dose of ANV419.~Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to calculate the dose of ANV419.
Study: NCT05898152

Intervention type: OTHER
Intervention: Data collection
Description: A collection about patient's data demographic, neurologic and gynecologic follow-up and satisfaction will be review by questionnaire. And a calendar of epileptic seizures will be completed by patients on 4 months